The abstract is read at the publisher; the summary is JClub's.
Microenvironment classification is positioned as a key approach to personalize cell and immune therapies for large B-cell lymphoma, aiming to address the lack of durable benefit in most patients.
- Why it matters: Most patients with lymphoma do not achieve durable benefit from cell and immune therapies, highlighting a need to better tailor treatment to tumor and immune context.
- What they did: The work outlines a pathway that combines discovery, validation, and clinical deployment of microenvironment classification to guide precision immunotherapy choices.
- The result: By enabling microenvironment-informed personalization, this framework is intended to improve how cell and immune therapy approaches are selected and deployed for large B-cell lymphoma patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.